Skip to main navigation

Investor Relations

  • About Eton
      • Mission & Values
      • Our Business Model
      • Leadership Team
      • Board of Directors
      • Careers
  • Pipeline
  • Eton News
  • Investors
      • Overview
      • News Releases
      • Events & Presentations
      • Stock Information
      • Corporate Governance
      • SEC Filings
      • Contact IR
  • Contact Us

Investor Relations

  • About Eton
      • Mission & Values
      • Our Business Model
      • Leadership Team
      • Board of Directors
      • Careers
      • Close
  • Pipeline
  • Eton News
  • Investors
      • Overview
      • News Releases
      • Events & Presentations
      • Stock Information
      • Corporate Governance
      • SEC Filings
      • Contact IR
      • Close
  • Contact Us
  • Eton Pharma Missions & Values

Corporate Governance

Governance Documents
Audit Committe
Code of Business Conduct and Ethics
Compensation Committee
Nominating & Corporate Governance Commitee

Committees Composition

Audit Compensation Nominating and Corporate Governance
Mark Baum
Sean Brynjelsen
Charles J. Casamento Audit Compensation Nominating and Corporate Governance
Paul V. Maier Audit Compensation Nominating and Corporate Governance
Dr. Norbert Riedel Audit Compensation Nominating and Corporate Governance
= Chairperson = Member = Financial Expert
Email Alerts

Investor Relations

  • + Documents & Charters

  • + Management Team

  • + Board of Directors

Scroll

21925 W Field Pkwy #235
Deer Park, IL 60010
(847) 787 – 7361

NAVIGATION

Mission & Values
Our Business Model
Leadership Team
Product Pipeline
Investors & Media
News

Careers at Eton

RECENT ETON NEWS
  • Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE
    January 14, 2021
  • Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
    December 17, 2020
©2021 Eton Pharmaceuticals, Inc. Concept & Design by Menagery, Inc.